Mary Mader, PhD

Chemistry Strategy Advisor

Dr. Mary Mader is an accomplished medicinal chemist with a career spanning pharmaceutical, biotech, and not-for-profit drug discovery.  

Mary earned her Ph.D. in Organic Chemistry from the University of Notre Dame and completed an NIH postdoctoral fellowship at the University of California, Berkeley.

During her time at Eli Lilly and Company and Relay Therapeutics, she contributed to the development of multiple clinical candidates in oncology, with a focus on kinase and epigenetic targets.

She has held key leadership roles in the scientific community, including chairing the Medicinal Chemistry Gordon Research Conference and the inaugural Gordon Research Seminar in Medicinal Chemistry.

She has served on the editorial board of Molecular Cancer Therapeutics and as working group chair of Chemistry in Cancer Research for the AACR. In addition, she currently chairs the Discovery Expert Scientific Advisory Committee (ESAC) of the Medicines for Malaria Venture and is an advisory board member for multiple biotech firms. Mary is recognized for her deep scientific insight and collaborative approach to advancing drug discovery.
‍